Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
EXTON, Pa., April 13, 2017 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, Chief Executive Officer, will present at the 7th Annual World Orphan Drug Congress USA on Friday, April 21 at 2:30 pm EDT in Washington, D.C., and the Alliance for Regenerative Medicine’s (ARM) 5th Annual Cell & Gene Therapy Investor Day on Thursday, April 27 at 4:15 pm EDT in Boston, Massachusetts.
A live webcast of Fibrocell’s presentation at ARM’s Cell & Gene Therapy Investor Day will be available under the investor relations section of the Company’s website at www.fibrocell.com/investors/events and archived for 30 days. Please visit Fibrocell’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, has begun a Phase I/II trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of linear scleroderma. In addition, Fibrocell has a third program in the research phase for the treatment of arthritis and related conditions. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit http://www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact: Karen Casey 484.713.6133 [email protected]
